Profile data is unavailable for this security.
About the company
Prescient Therapeutics Limited is a clinical-stage oncology company. It is engaged in developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, CellPryme-M, and OmniCAR. PTX-100 is a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. PTX-100 is in a Phase 2a clinical study in refractory/relapsed Cutaneous T Cell Lymphoma with Fast Track Designation. CellPryme-M is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. OmniCAR is a universal CAR platform that is controllable, with plug and play capabilities to enable a wider range of cancers to be targeted. OmniCAR enables controllable T-cell activity and multiantigen targeting with a single cell product.
- Revenue in AUD (TTM)225.61k
- Net income in AUD-7.32m
- Incorporated1986
- Employees3.00
- LocationPrescient Therapeutics LtdSuite 2, Level 11, 385 Bourke StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39692-7222
- Fax+61 39077-9233
- Websitehttps://ptxtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argenica Therapeutics Ltd | 332.69k | -9.80m | 35.97m | -- | -- | 10.45 | -- | 108.11 | -0.0762 | -0.0762 | 0.0026 | 0.0268 | 0.0323 | -- | 1.79 | -- | -95.10 | -47.11 | -117.81 | -55.90 | -- | -- | -2,945.67 | -2,938.71 | -- | -40,666.84 | 0.00 | -- | 166.93 | 359.61 | -30.86 | -- | -- | -- |
| Anteotech Ltd | 1.03m | -6.76m | 41.62m | 40.00 | -- | 12.02 | -- | 40.50 | -0.0025 | -0.0025 | 0.0004 | 0.0012 | 0.1299 | -- | 6.90 | -- | -85.41 | -76.84 | -106.22 | -87.65 | -- | -- | -657.69 | -1,253.69 | -- | -- | 0.3835 | -- | 99.60 | 27.97 | 23.89 | -- | -4.02 | -- |
| Neuroscientific Biopharmaceuticals Ltd | 166.08k | -1.85m | 43.23m | -- | -- | 2.57 | -- | 260.33 | -0.0126 | -0.0126 | 0.0011 | 0.0506 | 0.0148 | -- | 2.17 | -- | -16.48 | -37.13 | -16.65 | -40.11 | -- | -- | -1,111.22 | -185.57 | -- | -746.17 | 0.00 | -- | -93.05 | 16.84 | -669.23 | -- | -- | -- |
| Emyria Ltd | 1.39m | -3.14m | 44.36m | -- | -- | 6.34 | -- | 31.80 | -0.0069 | -0.0069 | 0.0031 | 0.0087 | 0.2316 | -- | 40.72 | -- | -52.19 | -82.51 | -69.83 | -106.69 | 1.76 | -17.98 | -225.33 | -355.61 | -- | -22.44 | 0.1037 | -- | -36.68 | 6.60 | 72.57 | -- | -41.45 | -- |
| Entropy Neurodynamics Ltd | 1.59m | -5.33m | 50.05m | -- | -- | 7.72 | -- | 31.53 | -0.0043 | -0.0043 | 0.0012 | 0.0041 | 0.2249 | -- | 0.763 | -- | -75.55 | -- | -92.06 | -- | -- | -- | -335.91 | -- | -- | -100.79 | 0.00 | -- | -- | -10.25 | -- | -- | -26.73 | -- |
| Syntara Ltd | 7.48m | -12.26m | 57.16m | 107.00 | -- | 3.55 | -- | 7.64 | -0.0084 | -0.0054 | 0.0051 | 0.0099 | 0.4701 | -- | 2.53 | -- | -77.03 | -36.39 | -116.54 | -50.26 | -- | -- | -163.86 | -78.37 | -- | -953.38 | 0.0052 | -- | 37.80 | -9.83 | 10.31 | -- | -- | -- |
| Clever Culture Systems Ltd | 6.52m | 1.68m | 63.01m | 17.00 | 37.18 | 9.08 | 33.01 | 9.66 | 0.0008 | 0.0008 | 0.0031 | 0.0032 | 0.6975 | 0.9829 | 6.37 | -- | 18.01 | -36.73 | 22.73 | -42.00 | 77.05 | -- | 25.82 | -281.21 | 1.63 | -- | 0.2653 | -- | 397.86 | 30.08 | 145.03 | -- | 24.71 | -- |
| Amplia Therapeutics Ltd | 5.01m | -7.93m | 64.13m | 1.00 | -- | 1.49 | -- | 12.81 | -0.0204 | -0.0204 | 0.0128 | 0.0837 | 0.1705 | -- | 1.28 | -- | -27.01 | -27.37 | -28.31 | -30.38 | -- | -- | -158.46 | -180.53 | -- | -- | 0.0088 | -- | -15.01 | 156.11 | -45.93 | -- | -- | -- |
| Prescient Therapeutics Ltd | 225.61k | -7.32m | 71.50m | 3.00 | -- | 4.81 | -- | 316.93 | -0.0091 | -0.0091 | 0.0003 | 0.0141 | 0.0129 | -- | 0.9582 | -- | -41.90 | -31.70 | -49.69 | -34.33 | -- | -- | -3,245.66 | -2,146.75 | -- | -590.48 | 0.00 | -- | -67.19 | 26.24 | 11.11 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 3.31m | -8.11m | 73.51m | -- | -- | 5.53 | -- | 22.19 | -0.0605 | -0.0605 | 0.0247 | 0.0805 | 0.2582 | -- | 12.02 | -- | -63.57 | -63.62 | -68.88 | -71.91 | -- | -- | -246.18 | -222.10 | -- | -- | 0.021 | -- | 1.34 | 15.81 | -27.27 | -- | -54.88 | -- |
| Rhythm Biosciences Ltd | 3.33m | -3.83m | 80.13m | -- | -- | 107.79 | -- | 24.09 | -0.0134 | -0.0134 | 0.0124 | 0.0023 | 1.53 | 98.79 | 67.11 | -- | -176.04 | -146.24 | -469.96 | -197.40 | -10.44 | 22.48 | -115.14 | -287.42 | 0.8046 | -53.89 | 0.6266 | -- | 90.87 | 135.14 | 44.15 | -- | -12.61 | -- |
| Imugene Ltd | 0.00 | -69.02m | 86.81m | 0.00 | -- | 1.32 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.205 | 0.00 | -- | -- | -- | -58.75 | -48.72 | -75.21 | -53.73 | -- | -- | -- | -- | -- | -- | 0.1913 | -- | -- | -- | 53.89 | -- | 38.40 | -- |
| Cynata Therapeutics Ltd | 227.70k | -9.39m | 92.61m | 0.00 | -- | 14.73 | -- | 406.71 | -0.0453 | -0.0453 | 0.0011 | 0.0265 | 0.0292 | -- | 2.16 | -- | -120.50 | -48.36 | -142.29 | -53.09 | -- | -- | -4,124.10 | -576.20 | -- | -1,268.00 | 0.00 | -- | -45.49 | 28.12 | 3.63 | -- | -- | -- |
| Alterity Therapeutics Ltd | 446.29k | -12.15m | 97.88m | 9.00 | -- | 1.94 | -- | 219.32 | -0.002 | -0.002 | 0.00007 | 0.0047 | 0.0137 | -- | 5,578.63 | 49,587.78 | -37.23 | -49.00 | -43.12 | -57.35 | -- | -- | -2,721.96 | -9,708.51 | -- | -211.82 | 0.0037 | -- | 66.27 | 91.97 | 36.48 | -- | -- | -- |
| Tetratherix Ltd | 1.14m | -9.43m | 103.00m | -- | -- | 7.00 | -- | 90.14 | -0.1873 | -0.1873 | 0.0227 | 0.5414 | 0.0688 | -- | 2.22 | -- | -56.71 | -- | -76.72 | -- | -172.06 | -- | -824.89 | -- | -- | -98.75 | 0.0697 | -- | 32.30 | -- | -269.05 | -- | -- | -- |
| LTR Pharma Ltd | 2.10m | -5.59m | 103.58m | -- | -- | 3.27 | -- | 49.24 | -0.0333 | -0.0333 | 0.0126 | 0.1741 | 0.1183 | -- | 8.22 | -- | -31.44 | -- | -32.47 | -- | -- | -- | -265.90 | -- | 45.76 | -62.54 | 0.00 | -- | 4,164.38 | -- | 19.57 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Prescient Therapeutics Ltd's reporting currency: Australian Dollar AUD
1.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Netwealth Investments Ltd.as of 30 Jun 2025 | 11.02m | 1.05% |
Data from 02 Feb 2026 - 02 Feb 2026Source: FactSet Research Systems Inc.
